Provectus Biopharmaceuticals Alpha and Beta Analysis
| PVCTDelisted Stock | USD 0.11 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Provectus Biopharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Provectus Biopharmaceutica over a specified time horizon. Remember, high Provectus Biopharmaceutica's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Provectus Biopharmaceutica's market risk premium analysis include:
Beta 0.45 | Alpha (0.33) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Provectus |
Provectus Biopharmaceutica Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Provectus Biopharmaceutica market risk premium is the additional return an investor will receive from holding Provectus Biopharmaceutica long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Provectus Biopharmaceutica. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Provectus Biopharmaceutica's performance over market.| α | -0.33 | β | 0.45 |
Provectus Biopharmaceutica Fundamentals Vs Peers
Comparing Provectus Biopharmaceutica's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Provectus Biopharmaceutica's direct or indirect competition across all of the common fundamentals between Provectus Biopharmaceutica and the related equities. This way, we can detect undervalued stocks with similar characteristics as Provectus Biopharmaceutica or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Provectus Biopharmaceutica's fundamental indicators could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Provectus Biopharmaceutica to competition |
| Fundamentals | Provectus Biopharmaceutica | Peer Average |
| Return On Asset | -1.85 | -0.14 |
| Operating Margin | (4.77) % | (5.51) % |
| Current Valuation | 46.73 M | 16.62 B |
| Shares Outstanding | 419.55 M | 571.82 M |
| Shares Owned By Insiders | 3.69 % | 10.09 % |
| Shares Owned By Institutions | 0.04 % | 39.21 % |
| Number Of Shares Shorted | 1.82 M | 4.71 M |
Provectus Biopharmaceutica Opportunities
Provectus Biopharmaceutica Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Provectus Biopharmaceutica Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Provectus or other otcs. Alpha measures the amount that position in Provectus Biopharmaceutica has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Provectus Biopharmaceutica Upcoming Company Events
As portrayed in its financial statements, the presentation of Provectus Biopharmaceutica's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Provectus Biopharmaceutica's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Provectus Biopharmaceutica's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Provectus Biopharmaceutica. Please utilize our Beneish M Score to check the likelihood of Provectus Biopharmaceutica's management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Provectus Biopharmaceutica
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |